Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NGM120 in advanced solid tumors, pancreatic and prostate cancer
NCT04068896Phase 2Completed
- Sponsor
- NGM Biopharmaceuticals
- Start
- Oct 2019
- Primary completion
- Sep 2023
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of NGM120 in pancreatic adenocarcinoma (PDAC), metastatic castration-resistant prostate cancer (mCRPC), solid tumor, sponsored by NGM Biopharmaceuticals. Started Oct 2019; status: completed.
02
Drugs
NGM120
03
Conditions
pancreatic adenocarcinoma (PDAC)metastatic castration-resistant prostate cancer (mCRPC)solid tumor
Beyond the preview
Go deeper on NCT04068896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04068896.